Next Article in Journal
The Role of G-Protein-Coupled Receptor Proteolysis Site Cleavage of Polycystin-1 in Renal Physiology and Polycystic Kidney Disease
Next Article in Special Issue
Feedback Regulation of Kinase Signaling Pathways by AREs and GREs
Previous Article in Journal
MIRO GTPases in Mitochondrial Transport, Homeostasis and Pathology
Article Menu

Export Article

Open AccessReview

Re-Use of Established Drugs for Anti-Metastatic Indications

MetaVì Labs Inc., 16238 Ranch Road 620 North, Suite F-347, Austin, TX 78717, USA
Faculty of Health—School of Medicine, Witten/Herdecke University, Alfred-Herrhausen-Straße 50, 58448 Witten, Germany
Author to whom correspondence should be addressed.
Academic Editor: Ritva Tikkanen
Received: 21 November 2015 / Revised: 4 January 2016 / Accepted: 8 January 2016 / Published: 12 January 2016
(This article belongs to the Special Issue Signal Transduction 2016)
Full-Text   |   PDF [523 KB, uploaded 12 January 2016]   |  


Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication. View Full-Text
Keywords: cancer; metastasis; cell migration; drug screening cancer; metastasis; cell migration; drug screening

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Entschladen, F.; Thyssen, D.A.; Drell, D.W. Re-Use of Established Drugs for Anti-Metastatic Indications. Cells 2016, 5, 2.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top